BamSEC and AlphaSense Join Forces
Learn More

ANI Pharmaceuticals Inc.

NASDAQ: ANIP    
Share price (12/23/24): $54.21    
Market cap (12/23/24): $1.140 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.5
from 10-Q 10 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.4
from 10-Q 3 pages ANI Pharmaceuticals, Inc. (The “Company”) the Company’s Amended and Restated 2022 Stock Incentive Plan (The “Plan”) Sub-Plan for U.K. Employees
12/34/56
EX-10.1
from 8-K 20 pages Contingent Value Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages [Dealer]1
12/34/56
EX-10.1
from S-8 14 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan
12/34/56
EX-10.1
from 8-K 13 pages Voting Agreement
12/34/56
EX-10.3
from 8-K 4 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.2
from 8-K 4 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.1
from 10-Q 27 pages [***] Certain Information Contained in This Document Has Been Omitted Based on a Court Order. Assignment and Technology Transfer Agreement Between Biosante Pharmaceuticals, Inc. and Cold Genesys, Inc. Dated as of November 15, 2010 Assignment and Technology Transfer Agreement
12/34/56
EX-10.34
from 10-K 9 pages Form of Indemnification Agreement
12/34/56
EX-10.33
from 10-K 1 page Notice of Termination
12/34/56
EX-10.32
from 10-K 3 pages Amendment to Agreement of Purchase and Sale
12/34/56
EX-10.31
from 10-K 20 pages Article 1 Interpretation
12/34/56
EX-10.24
from 10-K 2 pages Amendment No. 2024-2 to ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan February 5, 2024
12/34/56
EX-10.1
from 8-K 22 pages Article 1 Interpretation
12/34/56
EX-10.1
from S-8 6 pages Amendment No. 2023-1 to ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Effective May 23, 2023
12/34/56
EX-10
from 10-Q 45 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 46 pages Executive Employment Agreement
12/34/56
EX-10.2
from 10-Q 47 pages ​ Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” ​ Asset Purchase Agreement ​ Between ​ Holmdel Pharmaceuticals, LP ​ and ​ ANI Pharmaceuticals, Inc. ​ Dated as of February 23, 2017 ​
12/34/56
EX-10.1
from 10-Q 45 pages ​ Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Such Excluded Information Has Been Marked With “[***].” ​ Asset Purchase Agreement ​ Between ​ Cranford Pharmaceuticals, LLC ​ and ​ ANI Pharmaceuticals, Inc. ​ Dated as of February 23, 2017 ​
12/34/56